Loading clinical trials...

Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder. | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.

A Multicentre 12-week Randomised Double-blind Placebo Controlled Feasibility Trial of Sodium Benzoate and/or N-acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.

NCT03510741•Pakistan Institute of Living and Learning

View on ClinicalTrials.gov

Summary

This study aims to determine if the addition of Sodium Benzoate and / or NAC to TAU will be acceptable and tolerable and result in overall improvement of symptoms, social and cognitive functioning in patients with early schizophrenia spectrum disorder.

Eligibility

Age

18 - 35 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male/Female patients aged between 18-35 years.
•2. Diagnosis of schizophrenia confirmed by SCID interview meeting DSM-V criteria for schizophrenia, schizophreniform or schizoaffective psychosis.
•3. Stable on medication for the past four weeks
•4. In contact with mental health services
•5. Within 5 years of diagnosis of psychotic illness
•6. Able to demonstrate the capacity to provide informed consent as assessed by their own clinician
•7. Able to complete the required evaluations and take oral medication.

Exclusion Criteria

•1. Prior history of intolerance or serious side effects to Sodium Benzoate or N-acetylcystine.
•2. Concomitant use of Ascorbic acid
•3. Active substance abuse (except nicotine or caffeine) or dependence within the last three months according to DSM-V criteria.
•4. Relevant CNS or other medical disorders.
•5. Pregnant or breast feeding
•6. Diagnosis of Moderate to Severe Learning Disability
•7. Relevant current or past haematological, hepatic, renal, neurological or other medical disorder in the opinion of the principal investigator (PI) or the responsible clinician, that may interfere with the trial.

Locations (5)

Balochistan Institute of Behavioral Science

Quetta, Balochistan, Pakistan

Institute of Psychiatry, Rawalpindi

Rawalpindi, Islamabad, Pakistan

Abbasi Shaheed Hsopital

Karachi, Sindh, Pakistan

Civil Hospital Karachi

Karachi, Sindh, Pakistan

Karwan e Hayat

Karachi, Sindh, Pakistan

Key Dates

Start Date

January 1, 2019

Primary Completion Date

December 30, 2020

Completion Date

March 30, 2021

Last Updated

April 27, 2022

Enrollment

ACTUAL participants

Conditions

SchizophreniaSchizophreniform DisordersSchizoaffective Disorder

Interventions

Sodium Benzoate

DRUG

N-Acetylcysteine

DRUG

Placebo

DRUG

Sodium Benzoate Plus N-Acetylcysteine

DRUG

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 27, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Brain Stimulation to the Hippocampus in Schizophrenia

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques